Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B

Zhang, Hongliang; Wang, Jun; Ren, Tingting; Huang, Yi; Liang, Xin; Yu, Yan; Wang, Wei; Niu, Jianfang; Guo, Wei

doi:10.1016/j.canlet.2020.07.008

Cited by 102 publications

(82 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, miR-766-3p was lowly expressed in OS tissue specimens and cells, negatively related with OS malignancy, and might be used as a novel treating target for OS. Emerging research has demonstrated that the abnormal miRNA expression plays key regulatory role in OS progression (Czarnecka et al, 2020;Zhang H. et al, 2020), the potential mechanism of miR-766-3p has not been investigated. miR-766-3p has recently been recognized as a tumor suppressor through the β-catenin pathway in several tumors.…”

Section: Discussionmentioning

confidence: 99%

miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells

Zhang

Chen

Liu

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Accumulating evidence has indicated that abnormal microRNAs (miRNAs) serve critical roles in carcinogenesis and development of osteosarcoma (OS). The purpose of the present study was to elucidate the relationship between miR-766-3p and development of osteosarcoma and explore the potential mechanism. In this study, we found that miR-766-3p was the most downregulated miRNA by analyzing GSE65071 from the GEO database. miR-766-3p was lowly expressed in OS tissue samples and cells, and high miR-766-3p expression repressed the malignant level of OS, including cell proliferation, EMT, migration, and invasion in vitro and in vivo. B-Cell Lymphoma 9-Like Protein (BCL9L) was negatively associated with miR-766-3p expression in OS cells and tissue samples and was validated as the downstream target by luciferase reporter assay and western blotting. Rescue experiment indicated that BCL9L could restore the influence of miR-766-3p on OS cells. In addition, the β-Catenin/TCF-4 signal pathway was demonstrated to be related to the miR-766-3p/BCL9L axis. In summary, miR-766-3p, a negative regulator of BCL9L, plays the role of tumor metastasis suppressor via the β-catenin signaling pathway in the progression of OS.

show abstract

Section: Discussionmentioning

confidence: 99%

miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells

Zhang

Chen

Liu

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…MSCs and HEK293T cells are two commonly used cell types for producing miRNA-loaded EVs. The delivery of miRNAs (e.g., miR-206, 26a, 122, 126, 146b, 124a, and let-7a) by MSC-derived EVs has been described in osteosarcoma, [98] hepatocellular carcinoma (HCC), [62,99] NSCLC, [100] breast cancer, [101] and glioma and shown promising anti-tumor effects. [102,103] The transfer of miRNA inhibitors (anti-miR-9, [52] anti-miR-214, [104] anti-miR-374 [105] ) by EVs to cancer cells has also been reported.…”

Section: Rnamentioning

confidence: 99%

Engineered Extracellular Vesicles for Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

Extracellular vesicles (EVs) have emerged as a novel cell‐free strategy for the treatment of many diseases including cancer. As a result of their natural properties to mediate cell‐to‐cell communication and their high physiochemical stability and biocompatibility, EVs are considered as excellent delivery vehicles for a variety of therapeutic agents such as nucleic acids and proteins, drugs, and nanomaterials. Increasing studies have shown that EVs can be modified, engineered, or designed to improve their efficiency, specificity, and safety for cancer therapy. Herein, a comprehensive overview of the recent advances in the strategies and methodologies of engineering EVs for scalable production and improved cargo‐loading and tumor‐targeting is provided. Additionally, the potential applications of engineered EVs in cancer therapy are discussed by presenting prominent examples, and the opportunities and challenges for translating engineered EVs into clinical practice are evaluated.

show abstract

“…A number of studies have shown that EVs derived from mesenchymal stem cells (MSCs) can be used for stem cell replacement therapy [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21]. In most cases, it is not clear which component of the unmodified EVs exerts curative effects.…”

Section: Therapeutic Application Of Natural Evs As Cell Substitutesmentioning

confidence: 99%

“…In addition, some reports suggest that some EVs derived from mesenchymal stem cells contain some tumor suppressor molecules. For example, it has been reported that miR-206 in exosomes derived from bone marrow mesenchymal stem cells could inhibit the progression of osteosarcoma by targeting TRA2B [20]. The exosomes derived from human umbilical cord mesenchymal stem cells deliver miRNA-375 to delay the progression of esophageal squamous cell carcinoma [21].…”

Section: Evs Derived From Stem Cells and The Damage Repair And Regenementioning

confidence: 99%

“…Because they have anti-inflammatory, anti-apoptotic and anti-microbial capability, and promote angiogenesis and the repair and regeneration of damaged tissues. As mentioned above, EVs derived from MSCs have been widely used in the treatment of central nervous system diseases, cardiovascular diseases, bone and cartilage damage repair and regeneration, wound repair, and other organ damage repair and regeneration [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Extracellular Vesicles: “Stealth Transport Aircrafts” for Drugs

Liu¹,

Lin²,

Su³

2020

Theranostics - An Old Concept in New Clothing [Working Title]

View full text Add to dashboard Cite

Extracellular vesicles (EVs) can deliver many types of drugs with their natural source material transport properties, inherent long-term blood circulation capabilities and excellent biocompatibility, and have great potential in the field of drug carrier. Modification of the content and surface of EVs according to the purpose of treatment has become a research focus to improve the drug load and the targeting of EVs. EVs can maximize the stability of the drugs, prevent immune clearance and achieve accurate delivery. Therefore, EVs can be described as \" stealth transport aircrafts \" for drugs. This chapter will respectively introduce the application of natural EVs as cell substitutes in cell therapy and engineered EVs as carriers of nucleic acids, proteins, small molecule drugs and therapeutic viral particles in disease treatment. It will also explain the drug loading and modification strategies of EVs, the source and characteristics of EVs. In addition, the commercialization progress of EVs drugs will be mentioned here, and the problems in their applications will be discussed in conjunction with the application of EVs in the treatment of COVID-19.

show abstract

Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B

Cited by 102 publications

References 33 publications

miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells

miR-766-3p Targeting BCL9L Suppressed Tumorigenesis, Epithelial-Mesenchymal Transition, and Metastasis Through the β-Catenin Signaling Pathway in Osteosarcoma Cells

Engineered Extracellular Vesicles for Cancer Therapy

Extracellular Vesicles: “Stealth Transport Aircrafts” for Drugs

Contact Info

Product

Resources

About